Questions? +1 (202) 540-8337 Login
Trusted News Since 1995
A service for medical industry professionals · Tuesday, September 25, 2018 · 463,010,217 Articles · 3+ Million Readers

Hepatitis C Syndrome Diagnosis, treatments and Global Key players H1 2017

Hepatitis C

Hepatitis C

PUNE, MAHARASHTRA, INDIA, April 3, 2018 /EINPresswire.com/ -- Hepatitis C  

Overview

Hepatitis C is a contagious viral infection affecting the liver. It may spread on contact with infected blood. It may be a mild condition or may extend over a longer span of time leading to various complications. The characteristic symptoms include abdominal pain, fatigue, fever, jaundice, loss of appetite, nausea and vomiting The predisposing factors of hepatitis C include dialysis, organ transplant and blood transfusion. Offspring of an infected mother also has high chances of contracting the disease. Hepatitis C can be controlled with the help of medications or a transplant at an advanced stage.

 Click here for sample report @ http://www.wiseguyreports.com/sample-request/1248526-hepatitis-c-pipeline-review-h1-2017

Hepatitis C Industry Major Outlook

The Pharmaceutical and Healthcare latest pipeline guide Hepatitis C – Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Hepatitis C (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Hepatitis C (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Hepatitis C and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 4, 13, 23, 15, 1, 52, 45 and 4 respectively. Similarly, the Universities portfolio in Phase II, IND/CTA Filed, Preclinical and Discovery stages comprises 3, 1, 9 and 23 molecules, respectively.

Hepatitis C (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Hepatitis C (Infectious Disease). 
- The pipeline guide reviews pipeline therapeutics for Hepatitis C (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources. 
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. 
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. 
- The pipeline guide reviews key companies involved in Hepatitis C (Infectious Disease) therapeutics and enlists all their major and minor projects. 

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. 
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. 
- Find and recognize significant and varied types of therapeutics under development for Hepatitis C (Infectious Disease). 
- Classify potential new clients or partners in the target demographic. 
- Develop tactical initiatives by understanding the focus areas of leading companies. 
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics. 

Table of Contents 
Table of Contents 2 
Introduction 6 
Hepatitis C - Overview 7 
Hepatitis C - Therapeutics Development 8 
Hepatitis C - Therapeutics Assessment 29 
Hepatitis C - Companies Involved in Therapeutics Development 39 
Hepatitis C - Drug Profiles 74 
Hepatitis C - Dormant Projects 388 
Hepatitis C - Discontinued Products 405 
Hepatitis C - Product Development Milestones 410 
Appendix 424

List of Tables 
Number of Products under Development for Hepatitis C, H1 2017 
Number of Products under Development by Companies, H1 2017 
Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017 
Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017 
Number of Products under Development by Companies, H1 2017 (Contd..3), H1 2017 
Number of Products under Development by Companies, H1 2017 (Contd..4), H1 2017 

 …Continued

 For Detailed Reading Please visit @ https://www.wiseguyreports.com/reports/1248526-hepatitis-c-pipeline-review-h1-2017

About Us

Wise Guy Reports is part of the Wise Guy Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe. Wise Guy Reports understand how essential statistical surveying information is for your organization or association. Therefore, we have associated with the top publishers and research firms all specialized in specific domains, ensuring you will receive the most reliable and up to date research data available.

Contact Us:

NORAH TRENT

Partner Relations & Marketing Manager

sales@wiseguyreports.com

www.wiseguyreports.com

Ph: +1-646-845-9349 (US)

Ph: +44 208 133 9349 (UK)

Norah Trent
WiseGuy Research Consultants Pvt. Ltd.
+1 646 845 9349 / +44 208 133 9349
email us here

Powered by EIN Presswire